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Abstract
Background: People with depression/anxiety are twice as likely to smoke and are less responsive to standard tobacco
treatments, leading to a reduced life expectancy of up to 13.6 years compared to people without depression/anxiety.
However, this group of smokers is motivated to quit, and as a result of quitting smoking, their depression/
anxiety is likely to improve. In England, people with depression/anxiety are referred to a primary care-based psychological
therapies service known as ‘Improving Access to Psychological Therapies’ (IAPT), which could offer smoking cessation
treatment as part of usual care but currently does not. In this study, we aim (1) to establish the feasibility and acceptability
of delivering a smoking cessation treatment alongside IAPT usual care and (2) to establish the feasibility of a multi-centre
randomised trial to compare the combined smoking cessation and IAPT treatment to usual IAPT treatment alone.
Methods: A randomised and controlled, multi-centre trial to test the acceptability, feasibility and implementation of
smoking cessation treatment as offered alongside usual IAPT care, compared to usual care alone, with nested qualitative
methods. We will include adult daily smokers with depression/anxiety, who would like help to quit smoking and are
about to start IAPT treatment. Follow-up will be conducted at 3-months after baseline. The main outcome will be
retention in the smoking cessation treatment. Secondary outcomes are smoking-related (biochemically-verified 7-day
point prevalence smoking cessation, number of cigarettes smoked per day, Heaviness of Smoking Index), mental
health-related (PHQ-9), service-related (number of ‘Did Not Attends’, number of planned and completed IAPT sessions),
acceptability and feasibility (participant and clinician acceptability and satisfaction of intervention as assessed by
questionnaires and qualitative interviews, interviews will also explore acceptability and feasibility of data collection
procedures and impact of smoking cessation treatment on usual care and mental health recovery) and
implementation-related (intervention delivery checklist, qualitative analysis of intervention delivery).
Discussion: If the intervention is shown to be acceptable, feasible and suitably implemented, we can conduct a randomised
controlled trial. In a future trial, we would examine whether adding smoking cessation treatment increases smoking
abstinence and improves depression and anxiety more than usual care, which would lead to long-term health improvement.
Trial registration: ISRCTN99531779
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Background
Smoking is the world’s leading cause of preventable ill-
ness and death [1]. One in every two smokers will die of
a smoking-related disease, unless they quit [2, 3]. In
high-income countries, smoking prevalence has de-
creased from 46% during the 1970s to about 19% in re-
cent years [4–6]. However, smoking prevalence amongst
people with mental disorders has declined only slightly
and is currently around 32.0% [7, 8]. In the UK, recent
estimates indicate that 33.7% of people with depression,
and 28.9% of people with anxiety smoke [7, 8]. They are
more heavily addicted, suffer from worse withdrawal [9,
10] and experience a 19% reduction in the odds of quit-
ting (odds ratio 0.81, 95% CI 0.67 to 0.97) [10], even
though they are motivated to quit [11]. These inequal-
ities contribute to a reduction in life expectancy of up to
13.6 years for people with depression/anxiety compared
to the general population [12, 13].
Traditionally, mental health and addictive behaviours
have been treated separately. More recently, there has
been a movement towards interventions that target both
mental health and addiction [14–16]. Studies in patients
with severe mental disorders or alcoholism have shown
that treating addiction and mental health in parallel re-
sults in meaningful improvements in both [17–21]. van
der Meer and colleagues conducted a Cochrane review
of smoking cessation treatments for people with current
and historical depression [21] and found that adding
psychosocial mood management to usual smoking cessa-
tion treatment (e.g., nicotine replacement therapy) mod-
erately increased cessation rates when compared to
usual smoking treatment alone (risk ratio of 1.47; 95%
confidence interval 1.13 to 1.92) [21], thus highlighting
the importance of psychological support during a quit
attempt for this group.
New evidence suggests that smoking can cause mental
illness [45], and that stopping smoking is associated with
mental health benefits equal to anti-depressant treat-
ment [22]. In England, people with depression/anxiety
have access to psychological therapy services, known as
‘Improving Access to Psychological Therapies’ (IAPT),
in which service users receive psychological therapies for
depression and anxiety. IAPT may be an ideal platform
for delivering smoking cessation treatment. However,
there have been no trials comparing the effectiveness of
offering smoking cessation treatment alongside usual
care, and therefore, it is unknown if such a treatment is
feasible and acceptable to service users and therapists,
and can be implemented into the service. We have spent
the last 9 months designing an intervention with stake-
holders to enhance intervention suitability. In this study,
we aim to assess: (1) the feasibility of recruiting and
retaining participants, collecting data required for a
full-sized RCT, and randomisation procedures; (2) the
acceptability of data collection procedures and the
smoking cessation treatment as delivered alongside usual
IAPT care, as perceived by IAPT therapists and study
participants; and (3) implementation of the smoking ces-
sation treatment programme.
Methods
Design
A randomised and controlled multicentre feasibility trial
with nested qualitative research will be conducted to test
the acceptability, feasibility and implementation of
smoking cessation treatment offered alongside usual
psychological care. The study has been registered
on the World Health Organization's International Clin-
ical Trials Registry Platform (ID: ISRCTN99531779).
Any changes to the methods outlined in this protocol
will be outlined in the report of the study findings.
Ethical review
This study received ethics approval from the National Health
Service (NHS) Research Ethics Committee on 19/03/2018
(IRAS ID: 239339). In the case that there are any protocol
modifications, these will be submitted for ethical review.
Setting
This is a multicentre study involving two Improving Ac-
cess to Psychological Therapies (IAPT) sites in the
UK (i.e., Bristol and Oxford). IAPT is a NHS
primary-care based psychological therapy service
(https://www.england.nhs.uk/mental-health/adults/iapt/).
IAPT offers low- and high-intensity evidence-based ther-
apies (e.g., cognitive behavioural therapy (CBT)) to
people with common mental disorders. Psychological
treatment is delivered by therapists named ‘psychological
wellbeing practitioners’ (PWPs) and usually consists of
six 30–45-minute sessions, delivered over the telephone
or face-to-face (further details below).
Project timeline
The study will be undertaken over 18 months, and the final
follow-up will be in September 2019 (see Additional file 1
for a detailed study timeline and Table 1 and Fig. 1 for a
‘Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT)’ [23] schedule of enrolment, inter-
ventions and assessments, and study flow chart).
Eligibility criteria
Participants (IAPT service users)
The inclusion criteria are as follows:
 Aged 18 years or older
 Has current diagnosis of depression (clinician-
administered PHQ-9 score of ≥ 10) and/or anxiety
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(clinician-administered GAD-7 score of ≥ 8) (note:
other mental health comorbidities are allowable)
 Self-reported, daily tobacco smoker of at least 1 year
 Interested in receiving help to quit smoking tobacco
 Eligible for IAPT treatment on a one-to-one basis
over the telephone or face-to-face
 About to start psychological therapy for depression/
anxiety in IAPT
The exclusion criteria are as follows:
 Already started IAPT treatment
 Considered too unwell by the research or IAPT
team
 Pregnant or breastfeeding
Psychological wellbeing practitioners (PWPs, IAPT
therapists)
The inclusion criteria are as follows:
 Aged 18 years or older
 Have provided psychological treatment to people
with depression/anxiety in IAPT for at least 2
years
 Available to attend training in delivering the
smoking cessation intervention
 Non- or ex-smoker
Withdrawal of participants
Patient and PWP participants can withdraw from the
study at any time, and they can withdraw their data from
the study at any time during the study period.
Payments to participants
Participants will not be paid for their contribution to
the study.
Intervention arm
In both the intervention and control groups, participants
will receive an evidence-based psychological therapy
(i.e., CBT), typically lasting 30–45minutes per session,
delivered over 6 sessions. In the intervention group only,
participants will receive a multi-component smoking
cessation treatment that includes behavioural, psycho-
logical and pharmacological support. PWPs will deliver
the smoking cessation treatment as parallel to usual
IAPT care (see Table 2). The smoking cessation treat-
ment package is an adapted version of the National
Centre for Smoking Cessation and Training’s (NCSCT)
standard treatment programme [24]. The NCSCT stand-
ard treatment programme is based on the most
up-to-date evidence available, is supported by the
Table 1 SPIRIT schedule of enrolment, interventions and assessments
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National Institute for Clinical Excellence and is proven
to be cost-effective in NHS settings [25, 26]. The smok-
ing cessation treatment will be delivered over the tele-
phone or face-to-face (i.e., depending on usual care) and
will be delivered on an individual basis. Based on inter-
views and consultation with stakeholders, the interven-
tion has been altered to best fit IAPT usual care, and
service user needs, while being mindful of the NCSCT’s
standard treatment programme.
Duration and number of sessions
Participants will receive 5–15 minutes of smoking ces-
sation treatment per IAPT appointment, delivered
over 6 IAPT usual care appointments. In Bristol,
PWPs will deliver smoking cessation treatment within
the usual care timeframe. In Oxford, PWPs will be al-
located an extra 5–15 minutes per IAPT appointment
to deliver the smoking cessation treatment. We pre-
dict that treatment will last approximately 12 weeks;
however, this is subject to the progress of the partici-
pant's IAPT care. During the first two IAPT appoint-
ments, 10–15 minutes will be allocated to delivering
the smoking cessation treatment, and the remaining
time will be used to deliver IAPT usual care. For the
following four IAPT appointments, 5–10 minutes will
be used to deliver the smoking cessation treatment,
and the remaining time will be used to deliver IAPT
usual care.
Fig. 1 Flow chart of study events
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Behavioural and psychological components
PWPs will offer behavioural support as outlined in
the NCSCT's standard treatment programme [24]. See
Table 2 for an outline of the modified version of the
standard treatment programme that will be delivered
in this study. In addition to behavioural support, par-
ticipants will receive psychoeducation about smoking
and mental health. New evidence suggests that smok-
ing can cause mental illness [45], and that stopping
smoking is associated with mental health benefits
equal to anti-depressant treatment [22]. This can par-
tially be explained by breaking the smoking with-
drawal cycle—in sum, nicotine has a short half-life,
and smokers start to experience the psychological
symptoms of withdrawal soon after having a cigarette,
for example, symptoms of low mood and anxiety.
Therefore, the smoker is in a constant state of with-
drawal, with short periods of relief only when they
are actively smoking and shortly after finishing a
cigarette. It may be that smokers mistake the ability
of smoking to relieve withdrawal symptoms to its
ability to relieve stress, anxiety and low mood. [27,
28]. Participants will receive an information pack
about quitting smoking and mental health via email,
leaflet or post.
Nicotine replacement therapy (NRT)
NRT will be provided at cost of prescription, or
free-of-charge (i.e., depending on site), alongside behav-
ioural support to use NRT (NCSCT and the British
National Formulary [24, 29]). NRT will be posted or par-
ticipants will be given a prescription request to present
at their local pharmacy (i.e., depending if IAPT care is
delivered over the telephone or face-to-face). In both
sites, participants will receive an information pack that
includes text and video instructions on how to take the
NRT. Participants who self-report having diabetes melli-
tus, renal impairment or hepatic impairment will be re-
ferred to their GP or pharmacy prescriber for NRT [29].
Table 2 Overview of treatment components
Session 1 2 3–5 6
Duration in minutes 10–15 10–15 5–10 5–
10
Smoking cessation treatment session Pre-
quit
Quit
day
Follow-
up
Final
Address participant beliefs about smoking and mental health ✓ ✓ ✓ ✓
Inform the participant about the treatment programme ✓
Assess current smoking ✓
Assess past quit attempts ✓
Explain how smoking dependence develops and assess nicotine dependence ✓
Explain the importance of abrupt cessation and the ‘not a puff’ rule ✓ ✓ ✓ ✓
Inform the participant about withdrawal symptoms ✓
Discuss stop smoking medications/products ✓
Set the quit date ✓
Prompt a commitment from the participant ✓ ✓
Check on participant progress ✓ ✓
Confirm participant readiness and ability to quit ✓
Confirm that the participant has a sufficient supply of stop smoking medication/products ✓ ✓ ✓
Give participant NRT vouchers or refer to pharmacy/GP for varenicline ✓ ✓ ✓ ✓
Enquire about medication use ✓ ✓
Discuss withdrawal symptoms and cravings, and how to cope ✓ ✓
Advise on changing routine ✓
CO-monitoring (i.e., site dependent) ✓ ✓ ✓ ✓
Discuss how to address the issue of the participant's smoking contacts and how the participant can get support
during their quit attempt
✓
Discuss any difficult situations experienced and methods of coping ✓ ✓
Address any potential high-risk situations in the coming week ✓ ✓
Discuss plans and provide a summary ✓ ✓ ✓ ✓
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Participants will be provided with two NRT products,
and the participant will have the opportunity to alter the
dose or type of NRT [24]. As per the NCSCT’s standard
treatment programme, participants will be provided with
nicotine patches, and the strength will depend on the
level of nicotine dependency as assessed using the
Heaviness of Smoking Index [30]. A second NRT prod-
uct will be recommended to help combat cravings—par-
ticipants will have a choice of a lozenge, gum, microtab,
nasal spray, mouth-spray, mini lozenges, or strips, with
strength depending on the level of nicotine dependency.
See Additional file 1 for the list of NRT products
available.
Varenicline
If the participant prefers not to use NRT or has previ-
ously used NRT as part of a behavioural treatment and
failed to quit, they will have the option of using vareni-
cline, pending confirmation from their GP/pharmacy.
The participant’s GP or pharmacist prescriber will pre-
scribe varenicline at their discretion. Participants will re-
ceive behavioural support for use of varenicline as
outlined by the NCSCT [24] and in Table 2.
E-cigarettes
PWPs will provide behavioural support to participants
who choose to use e-cigarettes to aid their quit attempt.
This follows recommendations from Public Health Eng-
land [31]. However, the study will not fund the purchase
of e-cigarettes or accessories.
Differences between NCSCT’s standard treatment
programme for smoking cessation and the smoking
cessation treatment offered in this study
To tailor the smoking cessation treatment to IAPT
usual care, we have interviewed PWPs, service man-
agers and service users (NHS National Research Eth-
ics Service review ID:225399. i.e., under write-up) and
consulted with current and prospective commissioners
for IAPT services. Based on interviews and consulta-
tions, we modified the NCSCT’s standard treatment
programme as follows:
1. Shortened total treatment time from 110minutes to
40 to 70minutes to meet IAPT service requirements
2. CO-monitoring will not be part of the intervention
in one of the sites, as IAPT care is predominately
telephone-based in one of the two sites
3. There will be an emphasis on addressing the
relationships between smoking, the withdrawal
cycle and links to mental health
Integrating smoking cessation treatment into IAPT usual
care
IAPT is predominately based on a guided self-help
model. The main aim of guided self-help is to sup-
port the service user in learning how to make positive
changes to their behaviour and thinking, to help im-
prove their mental health. With support from their
PWP, service users learn a toolkit of coping strategies
to help them to become their own therapist, so that
they can manage their mental health effectively and
prevent future setbacks. Pre-trial interviews with
PWPs and IAPT service users, and service managers
have identified that there are many psychological the-
ories and techniques that PWPs regularly use that
provide opportunities to deliver behavioural and psy-
chological support to aid smoking cessation, for ex-
ample, motivational interviewing, psychoeducation
and behavioural activation.
Control arm
Participants in the control arm will receive IAPT
usual care, plus contact details for their local smok-
ing cessation service during their final IAPT
appointment.
PWP training programme
A maximum of ten PWPs per site will be trained to de-
liver the treatment. PWPs will take part in the following
training:
1. NCSCT level 1 online training and assessment
programme
2. NCSCT level 2 face-to-face training
3. An overview about the importance of randomised
trial methodology and study procedures (e.g., data
recording)
4. A researcher will visit each service once a month to
listen in sessions and offer feedback to PWPs
Outcomes
The trial aims to assess: (1) the feasibility of recruiting
and retaining participants, collecting data required for a
full-sized RCT, and randomisation procedures, (2) the
acceptability of data collection procedures and the
smoking cessation treatment as delivered alongside usual
IAPT care, as perceived by PWPs and study participants,
and (3) implementation of the smoking cessation treat-
ment programme.
Main acceptability and feasibility outcome
 Study completers: Participants will be considered a
completer if they continue with smoking cessation
treatment up until the point of smoking cessation, a
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quit attempt, or completion of IAPT care. The
proportion of study completers will be calculated by:
N study completers
N randomised at baseline
Secondary acceptability and feasibility outcomes
 Recruitment into the trial
 Participant and PWP acceptability and satisfaction
of smoking cessation treatment (Modified version
of the Stop Smoking Service Client Satisfaction
Survey [32] and Modified version of a clinician
self-report intervention acceptability questionnaire
[33])
 Qualitative interviews with PWPs will explore PWP
perceptions of:
 Acceptability of the smoking cessation treatment
 Acceptability of data collection procedures
 Positive and negative impacts of smoking
cessation treatment on IAPT usual care and
mental health recovery
 Qualitative interviews with participants will explore
participant perceptions of:
 PWP ability to deliver the smoking cessation
treatment
 Acceptability of the smoking cessation treatment
 Positive and negative impacts of smoking
cessation treatment on IAPT usual care and
mental health recovery
Implementation outcomes
 Intervention Implementation Checklist: We will listen
to a proportion of smoking cessation treatment
sessions and note which intervention components
were delivered or not (Table 2)
 Observations and listening to intervention delivery
recordings
We will check data completeness for the following
outcomes
Smoking-related:
 Carbon monoxide (CO)-verified 7-day point prevalence
smoking cessation (i.e., validated by exhaled carbon
monoxide concentration of < 10 ppm (ppm) [34]. CO-
testing will be available on both sites via a 3 month
follow-up home visit.
 Number of cigarettes per day (CPD)
 Heaviness of Smoking Index (HSI) [35]
Mental health-related:
 Patient Health Questionnaire (PHQ-9) [36] score
Service-related:
 Number of ‘Did Not Attends’
 Number of planned, completed and missed IAPT
appointments
Sample size
Trial
Assuming a sample size of 100 participants at follow-up,
we used a standard formula to calculate the binomial
exact confidence interval [37, 38]. The study will have
sufficient power to estimate that 40% or more partici-
pants will continue with smoking cessation treatment in
the intervention arm with a 95% confidence interval of
26% to 55% (i.e., assuming the true rate is 40%).
Therefore, assuming that about 36% of participants
will be lost to follow-up [39], this study will require a
sample size of 157 at baseline:
i:e:; 157− 157
36
100
  
¼ 100
 
Interviews
We will aim to interview all PWPs who deliver the
smoking cessation treatment and 20 trial participants, or
until saturation is reached [40]. We will use a purposeful
sampling method and aim for variation across the sites
and participant final smoking status.
Recruitment and consent procedures
Trial
Researchers will search for potentially eligible partici-
pants via patient management software. Potentially eli-
gible participants will be posted study information at
least 2 weeks prior to their first IAPT appointment and
contacted by a researcher before their first IAPT ap-
pointment to discuss eligibility and gain oral informed
consent. The trial consent form is available in the
Additional file 1.
Audio recording of treatment sessions
Sessions are recorded as part of IAPT usual care, and
written informed consent is gained on the same day as
treatment by PWPs.
Interviews
During the 3 month follow-up, trial participants will be
recruited into interviews. PWPs involved in intervention
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delivery will be recruited into interviews after they
have finished delivering the smoking cessation inter-
vention to their final participant. Written or oral in-
formed consent will be obtained on the day of the
interview.
Randomisation and intervention assignment methods
Sequence generation
The randomisation sequence will be generated by a stat-
istician using Stata software. Randomisation will be
stratified by site and blocked, and participants will be
randomised using a 1:1 algorithm to ensure an equal
number of participants in the treatment and control
arms.
Allocation concealment mechanism
Allocation concealment will be ensured as the random-
isation code will not be released until the IAPT service
user has been recruited into the trial, which takes place
after participant eligibility has been assessed, participant
identifier has been recorded, and consent gained to take
part in the trial and to being randomly allocated to treat-
ment condition.
Implementation
Randomisation will be requested via RedCap by the re-
searcher who recruited and consented the participant
into the trial. RedCap will send a response to the re-
searcher informing them which treatment the partici-
pant will be receiving. Randomisation can only be
requested once and after participant identifier, eligibility
and consent have been recorded, and therefore, imple-
mentation cannot be influenced by the PWP, participant,
the research or clinical team.
Blinding
Due to the nature of the intervention, it is not possible
to blind participants and PWPs who deliver the inter-
vention. Quantitative 3 month follow-up outcome as-
sessments will be conducted by a researcher who will
be blinded to treatment allocation. Qualitative inter-
views will be conducted after quantitative outcomes as-
sessment, as it is possible that the researcher will
become unblinded during interviews. Outcome assessor
blinding will also be verified by self-report at final
follow-up.
Data collection
See Additional file 1 for full data management plan.
Table 3 List of variables, and who the variables will be collected by
Category Variable Collected by who* Are data collected as part of routine care?
Eligibility Eligibility criteria met Researcher No
Demographics Date of birth PWP/researcher Yes
Ethnicity PWP/researcher Yes
Gender PWP/researcher Yes
Education PWP/researcher Yes
Mental health Comorbid mental health conditions PWP/researcher Yes
PHQ-9 PWP/researcher Yes
GAD-7 PWP/researcher Yes
Smoking Smoking status PWP/researcher Yes, but not regularly
Smoking history PWP/researcher No
Cigarettes per day PWP/researcher No
Bio-verification of smoking status Researcher No
Smoking cessation medication used in intervention PWP No
Service Participant drop-out of IAPT PWP Yes
Planned, completed and missed IAPT appointments PWP/researcher Yes
Acceptability and
feasibility
Retention in smoking cessation intervention PWP No
Participant satisfaction with smoking cessation intervention PWP/researcher No
Clinician satisfaction with smoking cessation intervention Researcher No
Qualitative Interviews Researcher No
Implementation Audio recording of treatment session PWP Yes
Intervention implementation checklist Researcher No
*PWP = Psychological wellbeing practitioner
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Quantitative data collection
Table 1 and Fig. 1 present a schedule of data collection.
Most participant data will be collected as part of usual
care. Baseline and 3 month follow-up data will be col-
lected by a researcher. Usual care data will be recorded
by PWPs using patient management software and then
extracted and input into RedCap by researchers
(Table 3).
Qualitative data collection
We will collect two types of qualitative data:
1. Audio recordings of intervention delivery
2. Post-intervention interviews with PWPs and
participants
Intervention delivery audio recordings will be taken as
part of usual care, and only relevant sections, as decided
by a researcher, will be used for analysis (i.e., where
smoking cessation treatment is being delivered). We will
have access to these recordings and will sample 30 ran-
dom sessions to assess implementation.
Interviews will be conducted by a researcher, ideally
in-person, but also over the telephone upon request. In-
terviews will last no longer than 60 minutes and will be
conducted using flexible topic guides to ensure that the
same broad topics are covered in all interviews, while
allowing flexibility for interviewees to introduce new is-
sues [41]. Topic guides will be modified as necessary
throughout the course of the interviews to reflect find-
ings as they emerge. The interviewer will use open-
ended questioning techniques to elicit participants’ own
experiences and views, and participants will be asked to
provide examples to avoid reliance on ‘hypothetical’ ac-
counts. Interviews will be anonymised to protect confi-
dentiality. All interview data will be transcribed using a
university-approved service.
Post-trial care
If the participant would like to use smoking cessation
medication/products beyond their IAPT treatment, they
will be able to obtain a prescription from their GP or
local smoking cessation service. Participants will be re-
quired to pay a prescription dispensing fee, unless they
are exempt from paying for their prescriptions through
the NHS. If the participant was not successful in their
quit attempt, the PWP will provide them with contact
details to a local stop smoking service.
Adverse events
PWPs will check in with participants about the progress
of their quit attempt and the stop smoking medication/
products that they are using. In the case that a participant
is experiencing any unusual symptoms or events, PWPs
will use the NHS ‘Decision Tree for Adverse Event Report-
ing’ (see Additional file 1) to class and action adverse
events (i.e., any unfavourable and unintended signs, symp-
toms or a disease associated with treatment). Adverse
event(s) will be recorded in the study file with a note that
will identify when the event occurred, the details of the ad-
verse event(s), any potential study relation, action taken
and resolution/closure of the adverse event(s). An assess-
ment of seriousness will be made and will be reported to
the Chief Investigator and a Research Governance Officer.
Patient and public involvement
During study conceptualisation, the research aims and
study design were peer-reviewed by several members of
the public, and were presented to the UK Centre for To-
bacco and Alcohol Studies Smokers’ Panel and the Eliza-
beth Blackwell Institute’s Public Advisory Group for
feedback. In general, the study’s concept was well received,
understood, and thought to be an important area of re-
search. We will invite a patient member to trial manage-
ment meetings and involve patient and public panels in
analysis and dissemination.
Participant benefit
By taking part in this research, participants will assist in
the design and planning of an intervention to help
others quit smoking. Also, by choosing to take part, par-
ticipants will increase their chances of quitting smoking,
which is the single most important change one can make
to improve their health.
Quantitative analysis
Analyses will be conducted using Stata software.
Primary and secondary feasibility measures
We will present the number of participants who were
screened, randomised, treated, and followed up for primary
outcome in a CONSORT-style flow chart. The proportion
of study completers, by trial arm, will be calculated as:
N study completers
N randomised at baseline
Piloting main trial outcomes
The outcome measures which we intend to include in
the main trial will be piloted in this feasibility study. We
will present summary statistics by trial arm for each
measure at baseline and 3 month follow-up. Estimated
intervention effects will be presented with 95% confi-
dence intervals, these estimates being calculated using
regression models that include study site, the patient’s
PWP and baseline GAD-7 and PHQ-9 scores. Linear
regression will estimate differences in means for
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continuous measures, and logistic regression will esti-
mate odds ratios for binary measures. As this is a feasi-
bility study, these estimates will be too imprecise to
support definitive conclusions, but will be inspected for
evidence of a benefit of combining the smoking cessa-
tion treatment programme with IAPT usual care.
Sensitivity analyses
(1) We will conduct home visits with all participants
to CO-verify self-reported quits; however, it is possible
that some participants may decline/be unavailable for
a home-visit and therefore, in those cases, we will not
be able to obtain biological data. To account for this,
we will compare estimates derived from CO-verified
and self-reported 7-day point prevalence smoking ces-
sation. (2) Where data permit, we will compare the ap-
proaches in Bristol and Oxford for their acceptability
and feasibility.
We will develop a full statistical plan ahead of the data
analysis.
Qualitative analysis
We will conduct two qualitative analyses: (1) analysis of
intervention delivery recordings and (2) analysis of
qualitative interviews with PWPs and study participants.
Qualitative data will be analysed using a thematic ap-
proach, following guidance outlined by Braun and Clarke
[41]; thematic analysis will allow for both anticipated
themes (i.e., deductive coding) and emergent themes
(i.e., inductive coding). All data will be anonymised, and
to ensure the quality of data transcription, a researcher
will do a 50% check of audio data against the transcripts.
NVivo software will be used to code and apply the ana-
lytical framework.
Coding
One researcher will read the transcripts in full and will
re-listen to the audio recordings before coding the tran-
scripts, and then two researchers will read and conduct
a preliminary coding of a subset (i.e., a paraphrase,
label). Codes can refer to substantive things (e.g., behav-
iours, incidents, structures), values (e.g., beliefs about
smoking, treatment, rights), emotions (e.g., sadness, hap-
piness) and more methodological elements (e.g., inter-
viewee found something difficult to explain or became
emotional) [42].
Developing a framework
After coding three transcripts, researchers involved in
coding will meet to compare the labels that they have
applied and agree on a set of codes to apply to all
remaining transcripts. Codes will be grouped together
into categories, which are then clearly defined. The first
framework will act as a working analytical framework as
this may change after further coding of new transcripts.
After initial coding of all interviews using the working
analytical framework, all interviews will be re-read, and
codes re-examined for overlap and distinctiveness, and a
final framework of themes agreed. This framework will
form the basis for the structuring and presentation of
themes when writing up the qualitative findings.
Applying the analytical framework
The framework will be applied by indexing interview
transcripts using the existing categories and codes. Each
code will be assigned an abbreviation and will be given a
description, to ensure consistent application of codes
across the dataset. We will adopt a flexible approach,
and some codes may be grouped/merged or split as add-
itional transcripts are coded.
Discussion
In this protocol, we describe a feasibility study that
will examine both the feasibility of the intervention
and the feasibility of comparing the intervention with
IAPT usual care in a full randomised controlled trial
(RCT).
Strengths and limitations
In our previous study, we interviewed PWPs, service
managers and service users (NHS National Research
Ethics Service review ID: 225399, i.e., under write-up),
and consulted with current and prospective commis-
sioners for IAPT services in the aim of tailoring the
smoking cessation treatment to IAPT usual care. The
smoking cessation treatment package used in this study is
an adapted version of the National Centre for Smoking
Cessation and Training’s (NCSCT) standard treatment
programme [24]. The NCSCT standard treatment
programme is based on the most up-to-date evidence
available and is proven to be cost-effective in NHS set-
tings [25]. We tailored the NCSCT treatment package
to best suit the needs of the target population and
IAPT service. To optimise the likelihood of successful
delievery of the smoking cessation intervention in these
settings, we altered the NCSCT standard treatment
programme in three ways:
1. We shortened the total treatment time from 110
minutes to 40 to 70 minutes to meet IAPT service
requirements. It is possible that shortening
treatment time may limit the effectiveness of the
intervention. However, a recent Cochrane review
found no clear evidence that decreasing the
duration of personal contact time altered the effect
of combined behavioural and pharmacological
treatment for smoking cessation [43]. There is an
association between number of contacts offered for
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cessation and increased chances of quitting;
however, a Cochrane review found that this is not a
dose-response relationship and that offering four or
more contacts was more effective than offering
three or fewer contacts [44]; therefore, participants
in our study will be receiving an adequate number
of contacts (i.e., six appointments).
2. Carbon monoxide (CO) -monitoring will not be part
of the intervention in one of the sites, as IAPT care is
telephone-based in one of the two sites. During co-
design, we explored whether or not it was possible to
use CO-monitors in the behavioural programme;
however, feedback from PWPs and service managers
was unanimous and indicated that it was not feasible
to implement CO-monitoring these settings. We
cannot predict whether or not this will alter the
effectiveness of the smoking cessation interven-
tion, and our pilot and feasibility study will not
be large enough to explore the impact of this on
intervention effectiveness. However, if we find
that the intervention is feasible, accepted and
suitably implemented, this is something that we
can adjust for in a definitive RCT.
3. One aspect of this study that is not included in the
NCSCT Standard Treatment Programme but will
be added to the IAPT smoking cessation treatment
will be psychoeducation about smoking and mental
health. New evidence suggests that smoking can
cause mental illness [45], and that stopping
smoking is associated with mental health benefits,
potentially equivalent to taking anti-depressants
[22]. This evidence can partially be explained by
breaking the tobacco withdrawal cycle [27, 28]. In
summary, nicotine has a short half-life, and smokers
start to experience the psychological symptoms of
withdrawal soon after having a cigarette, for example,
symptoms of low mood and anxiety. Therefore, the
smoker is in a constant state of withdrawal, with
short periods of relief only when they are actively
smoking and shortly after finishing a cigarette. It may
be that smokers mistake the ability of tobacco to
relieve withdrawal symptoms to its ability to relieve
stress, anxiety and low mood [27, 28]. PWPs will inte-
grate this evidence into treatment sessions.
Conclusion
This study is expected to lead to new insights on
whether or not it is possible to deliver a collaboratively
designed smoking cessation treatment programme
alongside usual IAPT care as part of a holistic package
of mental health treatment. This study will also help de-
termine whether it is possible to evaluate integrat-
ing smoking cessation treatment into IAPT usual
care in a full RCT.
Additional file
Additional file 1: Online appendix for the ESCAPE trial. (DOCX 125 kb)
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